DTS Genomics
Pioneering the Future of Genomic Medicine
At DTS Genomics, we're revolutionizing healthcare through advanced whole genome sequencing and sophisticated data analytics. Our comprehensive genomic solutions empower patients, clinicians, and researchers with actionable insights that drive personalized medicine, accelerate scientific discovery, and transform health outcomes worldwide.
www.dtsgenomics.com
An ND Pharma & Biotech Stealth Company
Unveiling What is a Stealth Company
A "stealth company" operates with extreme secrecy, deliberately avoiding public attention during its early stages. This strategic approach allows them to innovate and develop groundbreaking products or services away from competitors' scrutiny, building a robust foundation before a grand unveiling.
The Public Company
Immediate Public Scrutiny: Operations, finances, and products are often visible from inception.
Early Market Buzz: Relies on public relations and marketing to generate early interest and investment.
Competitive Exposure: Development and strategic moves are often observable by rivals.
The Stealth Company
Extreme Secrecy: Operates under wraps, concealing its mission, team, and funding.
Focused Development: Prioritizes product innovation and refinement without external distractions.
Strategic Unveiling: Emerges when ready to capture market share and disrupt industries.
Why Operate in Stealth Mode?
Focused Development
Allows teams to concentrate solely on innovation and product perfection without market pressures or distractions.
Competitive Edge
Protects intellectual property and strategic insights from rivals until the product is ready for market impact.
Strategic Timing
Enables a meticulously planned launch, maximizing market entry impact and investor relations.
Stealth mode provides a critical incubation period, fostering a unique blend of secrecy, intense innovation, and strategic foresight.
Company Overview: Who We Are
Cutting-Edge Technology
DTS Genomics leverages proprietary whole genome sequencing and advanced analytics to provide comprehensive genomic insights with unparalleled accuracy and depth.
Mission-Driven Approach
We're dedicated to accelerating scientific discovery and delivering actionable genomic intelligence that empowers patients, clinicians, and researchers worldwide.
Expert Interpretation
Our team combines technical excellence with clinical expertise to translate complex genomic data into clear, actionable information for healthcare decisions.
Founded on the principle that genomic information should be comprehensive, accessible, and actionable, DTS Genomics stands at the intersection of biotechnology and data science. We've developed a unique platform that not only sequences the entire genome with exceptional accuracy but also interprets that data through sophisticated analytics to reveal meaningful health insights.
Our interdisciplinary team brings together expertise in genomics, bioinformatics, artificial intelligence, and clinical medicine to deliver solutions that address the complex challenges of modern healthcare. By providing a complete view of an individual's genetic makeup, we enable a new paradigm of care that is predictive, preventive, and truly personalized.
Our Vision: Precision Medicine for All an One
We envision a world where:
  • Genomic data is a standard component of every patient's health record
  • Preventive interventions are precisely tailored to individual genetic risk profiles
  • Treatment decisions are guided by comprehensive genetic insights
  • Genomic literacy empowers patients to make informed health choices
  • Advanced sequencing technology is accessible to all populations globally
At DTS Genomics, we're committed to democratizing access to comprehensive genomic information, ensuring that the benefits of precision medicine reach patients across all demographics and geographies. We believe that by providing deep genomic understanding at scale, we can fundamentally transform healthcare from a reactive to a proactive model, where disease prevention and early intervention become the norm.
Core Technology: Whole Genome Sequencing at 30x Coverage
Superior Depth & Accuracy
Our platform sequences the entire genome 30 times over (30x coverage), providing exceptional accuracy in variant detection and reducing false positives/negatives to near-zero levels.
Comprehensive Variant Analysis
We identify and analyze all types of genetic variants—from single nucleotide polymorphisms (SNPs) to complex structural variations and copy number changes that other tests might miss.
Complete Genomic Picture
Unlike limited panel tests or exome sequencing, our approach examines all 3 billion base pairs, including regulatory regions and non-coding DNA that play crucial roles in health and disease.
The foundation of DTS Genomics' precision medicine platform is our advanced whole genome sequencing (WGS) technology. By sequencing each base 30 times on average, we achieve the depth necessary to confidently identify rare and clinically significant genetic variations that lower-coverage methods frequently miss.
This comprehensive approach provides insights into inherited disorders, cancer predisposition, pharmacogenomic markers, and complex disease risk factors—all from a single test. Our technology captures the full spectrum of genetic variation, from single-base changes to large chromosomal rearrangements, giving clinicians the complete genomic picture needed for truly personalized care.
Completed with all the "omics" services, DTS Genomics is more that that, is Metabolomics, Proteomics, etc. (A handful of services to you).
Proprietary Data Analytics & Interpretation
Raw Sequencing Data
Billions of base pairs sequenced at 30x coverage generate massive datasets requiring sophisticated processing
Advanced Bioinformatics
Proprietary algorithms align, assemble, and identify variants with exceptional accuracy and efficiency
AI-Powered Analysis
Machine learning models assess variant pathogenicity by integrating multiple evidence sources and databases
Actionable Insights
Clinically relevant findings organized into clear, comprehensive reports customized for specific use cases
Converting raw genomic data into meaningful clinical insights requires extraordinary computational power and sophisticated analytical methods.
DTS Genomics has developed a proprietary bioinformatics pipeline that efficiently processes the massive datasets generated by whole genome sequencing while maintaining exceptional accuracy.
Our AI-driven interpretation platform continuously learns from emerging research, clinical outcomes, and our growing database of genomic variants. By integrating information from scientific literature, clinical databases, and functional studies, we provide context-rich assessments of genetic variants that guide clinical decision-making and research initiatives. The platform automatically updates interpretations as new evidence emerges, ensuring that insights remain current with the rapidly evolving field of genomics.
End-to-End Genomic Solutions
For Healthcare Providers
  • Streamlined clinical workflows with simple sample collection
  • Comprehensive reports tailored to medical specialties
  • Integration with electronic health records
  • Access to genetic counseling support for complex cases
  • Continuing medical education on genomic medicine
For Research Institutions
  • High-throughput sequencing for large cohorts
  • Custom bioinformatic analyses for specific research questions
  • Secure collaborative platforms for multi-institution projects
  • Biobanking and longitudinal data management
  • Publication-ready visualizations and datasets
DTS Genomics offers comprehensive solutions that address every aspect of the genomic testing process. From initial sample collection to final results delivery, we've designed an integrated workflow that maximizes efficiency, quality, and clinical utility. Our approach eliminates the complexity typically associated with genomic testing by providing a single platform that handles all technical aspects while delivering clear, actionable results.
For consumers and patients, we provide user-friendly reports, educational resources, and optional genetic counseling to ensure proper understanding of results and appropriate next steps. This end-to-end approach makes advanced genomic insights accessible to diverse users across healthcare, research, and consumer settings.
Clinical Lab in a Box: Bringing Genomics In-House
Turnkey Genomics Solution
Our Clinical Lab in a Box (CLIB) provides hospitals and medical centers with complete sequencing capabilities, including hardware, software, reagents, and workflow protocols, enabling in-house genomic testing without massive infrastructure investment.
Rapid Turnaround
By eliminating sample shipping and external processing delays, CLIB dramatically reduces time-to-result from weeks to days, enabling genomic insights to inform time-sensitive clinical decisions for critical cases.
Local Expertise Development
We provide comprehensive training and ongoing support to help institutions build internal genomics expertise, including laboratory technicians, bioinformaticians, and clinicians who interpret results.
DTS Genomics' innovative Clinical Lab in a Box solution addresses a critical gap in genomic medicine implementation. While centralized testing models have dominated the field, they introduce delays and disconnect the genomic data from the immediate clinical context. CLIB transforms this paradigm by enabling point-of-care genomic capabilities within healthcare institutions.
The system includes modular, scalable components that can grow with institutional needs, from initial focused applications to comprehensive genomic medicine programs. Our cloud-based interpretation platform ensures that even facilities with limited bioinformatics resources can generate clinically meaningful insights. This democratization of advanced genomic technology accelerates the integration of precision medicine into standard care across diverse healthcare settings.
Population Genomics & Research Partnerships
Advancing Population Health Through Genomics
DTS Genomics partners with health systems, government agencies, and research institutions to implement large-scale genomic studies that enhance our understanding of disease mechanisms and population-specific genetic factors. These initiatives generate valuable data sets that power discoveries and improve public health strategies.
Collaborative Research Network
Our consortium approach brings together diverse stakeholders to tackle complex genomic challenges, from rare disease diagnosis to pharmacogenomic implementation. By sharing expertise, resources, and data within appropriate ethical frameworks, we accelerate scientific progress and clinical translation.
500K+
Genomes Analyzed
Across diverse populations worldwide
75+
Research Partners
Academic, clinical, and industry collaborators
120+
Publications
Peer-reviewed discoveries enabled by our platform
Our population genomics initiatives enable precision public health approaches by identifying population-specific risk factors, pharmacogenomic markers, and disease mechanisms. These insights inform more targeted screening programs, intervention strategies, and healthcare resource allocation. For pharmaceutical partners, our platform accelerates drug discovery by identifying novel therapeutic targets and patient stratification biomarkers for clinical trials.
Impact Stories: Transforming Health Outcomes
Early Cancer Intervention
"DTS Genomics identified a BRCA2 mutation that my previous genetic tests had missed. This discovery led to enhanced screening that caught my breast cancer at stage 1, when it was fully treatable. I'm now cancer-free and advocating for comprehensive genomic testing for my entire family."
— Sarah K., Patient
Medication Optimization
"The pharmacogenomic profile from DTS Genomics revealed that I'm an ultra-rapid metabolizer of several psychiatric medications. This explained why standard doses weren't effective for me. My psychiatrist adjusted my treatment plan based on these insights, and I've finally found stability after years of struggling."
— Elena M., Patient
Accelerating Drug Development for BioPharma Innovations
"DTS Genomics' deep genomic insights were instrumental in our Phase 2 oncology trial. They helped us rapidly identify and stratify patients with specific rare genetic biomarkers, which significantly accelerated our recruitment efforts. This partnership cut our trial timeline by six months, allowing us to bring a vital new targeted therapy to patients faster."
— Dr. Alex Chen, Head of Clinical Development, BioPharma Innovations
Empowering Precision Medicine at Unity Health System
"Integrating DTS Genomics' 'Clinical Lab in a Box' solution revolutionized our in-house genomic testing capabilities. What once took weeks to outsource now happens in days, directly at our facility. This immediate access to comprehensive genomic data has dramatically improved our ability to deliver personalized diagnoses and treatment plans, enhancing patient care and significantly reducing operational costs."
— Maria Rodriguez, Director of Laboratory Services, Unity Health System
Clinical Impact Metrics
  • Diagnostic yield increase: 48% higher than standard genetic testing for rare diseases
  • Treatment modification: 32% of cases result in changes to medication or therapy based on genomic insights
  • Early intervention: 22% of hereditary cancer cases identified before clinical symptoms appear
  • Healthcare utilization: 35% reduction in diagnostic procedures after receiving comprehensive genomic information
These compelling stories from individuals, pharmaceutical companies, and leading health systems highlight the multifaceted impact of DTS Genomics. By uncovering crucial genetic information and providing cutting-edge solutions like 'Clinical Lab in a Box', we empower partners to accelerate research, optimize clinical trials, and deliver precision medicine that truly makes a tangible difference in individual lives and public health initiatives.
Innovation & R&D Pipeline
Multi-Omics Integration
Expanding beyond DNA to incorporate RNA sequencing, proteomics, metabolomics, and epigenetic analysis for a comprehensive molecular portrait that reveals how genetic variations influence biological processes in real time.
AI-Enhanced Variant Classification
Next-generation machine learning models that leverage our growing database of variants and outcomes to improve the accuracy of pathogenicity predictions, particularly for variants of uncertain significance.
Digital Twin Technology
Computational models that integrate genomic data with other health parameters to simulate disease progression and treatment responses, enabling personalized intervention strategies and virtual clinical trials.
At DTS Genomics, innovation is core to our mission. Our R&D team collaborates with leading academic institutions and technology partners to push the boundaries of what's possible in genomic medicine. We dedicate over 25% of our resources to developing next-generation technologies that will expand the clinical utility and accessibility of genomic information.
Our research initiatives are guided by real-world clinical needs identified through continuous feedback from healthcare providers and patients. This approach ensures that our innovations address practical challenges in implementing precision medicine across diverse healthcare settings. By maintaining a robust innovation pipeline, we're not just keeping pace with the rapidly evolving field of genomics—we're helping to shape its future.
Ethical Standards & Data Privacy
Comprehensive Data Protection
Military-grade encryption, secure cloud infrastructure, and rigorous access controls safeguard genomic data at every stage of processing and storage. Our systems undergo regular security audits and penetration testing.
Transparent Consent
Our detailed informed consent process clearly explains how genetic information will be used, stored, and potentially shared, with granular options for participants to control their data preferences.
Regulatory Compliance
Full adherence to HIPAA, GDPR, GINA, and regional genomic data regulations. Our dedicated compliance team monitors evolving requirements to ensure continued alignment with global standards.
"DTS Genomics' approach to ethical genomics sets a new standard for the industry. Their commitment to transparent consent, data sovereignty, and ongoing engagement with ethical questions demonstrates how technological innovation and ethical responsibility can advance together."
— Dr. Eleanor Harding, Chair of Bioethics, National Genomics Advisory Board
At DTS Genomics, we recognize that genomic data is uniquely personal and deserving of the highest protection standards. Our ethical framework extends beyond regulatory compliance to encompass equity in access, responsible research practices, and careful consideration of the societal implications of genomic technologies. We have established an independent Ethics Advisory Board composed of experts in bioethics, law, patient advocacy, and diverse community perspectives to guide our policies and practices.
Global Reach & Accessibility
Worldwide Operations
With sequencing laboratories and data centers across North America, Europe, and Asia, we provide localized support while maintaining global quality standards. Our platform is available in 28 countries and supports multiple languages.
Affordable Solutions
Through technological innovations and economies of scale, we've reduced the cost of comprehensive genomic analysis by 65% over the past three years. Flexible pricing models include institutional subscriptions and needs-based programs.
Strategic Partnerships
Collaborations with national health systems, NGOs, and foundation partners extend our reach to underserved regions and populations, helping bridge the global genomic divide through technology transfer and capacity building.
DTS Genomics is committed to democratizing access to advanced genomic technologies across geographical, economic, and cultural boundaries. We recognize that for genomic medicine to fulfill its promise, it must be available to diverse populations worldwide. Our scalable solutions adapt to various healthcare system structures, from integrated national services to distributed private networks.
Beyond technology deployment, we invest in genomic education programs for healthcare providers and community outreach to increase genomic literacy among the general public. These efforts help ensure that the benefits of genomic advances are shared equitably and that our reference databases reflect global genetic diversity, improving interpretations for all populations.
Industry Context: The Genomics Revolution
From Human Genome Project to Everyday Care
Since the completion of the first human genome sequence in 2003 at a cost of $3 billion, genomic technologies have undergone remarkable transformation. Today, whole genome sequencing is approaching standard-of-care status for conditions ranging from rare diseases to cancer, with costs under $1,000 and continuing to decrease.
Convergence of Technologies
The genomics revolution is accelerated by parallel advances in computing power, artificial intelligence, and digital health platforms. This convergence is enabling novel applications like digital twins for personalized disease modeling and predictive analytics for early intervention.
Diagnostic Testing
From rare disease diagnosis to cancer profiling, genomics is replacing traditional testing approaches with comprehensive analysis
Therapeutic Selection
Genomic biomarkers guide precise treatment matching, improving outcomes while reducing adverse effects
Drug Discovery
Genomic insights reveal new therapeutic targets and patient stratification approaches for clinical trials
Preventive Medicine
Identification of inherited risk factors enables personalized prevention strategies before disease onset
In this rapidly evolving landscape, DTS Genomics stands out by combining technological excellence with practical clinical implementation. While many companies focus solely on sequencing technology or data analysis, our integrated approach addresses the full spectrum of needs required to make genomic medicine a practical reality in everyday healthcare settings.
Gianni Contino · DTS Associate Researcher
Future Outlook: Shaping Healthcare by 2030
"By 2030, we envision a healthcare system where genomic information is as fundamental to clinical decision-making as blood pressure or temperature is today. The integration of comprehensive genomic data with other health parameters will enable truly predictive and preventive medicine, fundamentally changing our approach from treating disease to maintaining health."
— Dr. Marcus Chen, Chief Scientific Officer, DTS Genomics
DTS Genomics is actively developing the technologies and frameworks that will define the next decade of genomic medicine. Our research initiatives in digital twin technology aim to create personalized computational models that integrate genomic data with longitudinal health information, enabling simulation of disease progression and treatment responses at the individual level. These models will power a new generation of preventive interventions that are precisely calibrated to each person's unique genetic makeup and health history.
Simultaneously, we're working to establish collaborative data ecosystems that enable secure, consent-driven sharing of genomic insights across institutional and national boundaries. This approach will accelerate discoveries while respecting individual privacy and data sovereignty. Through these efforts, DTS Genomics is helping to build a future where genomic information becomes a cornerstone of healthcare worldwide.
Conclusion: Join Us on the Genomic Journey
For Healthcare Providers
Partner with DTS Genomics to integrate comprehensive genomic capabilities into your clinical practice. Our solutions can be tailored to institutional needs, from simple send-out testing to full on-site genomic laboratories with our Clinical Lab in a Box solution.
For Researchers
Leverage our advanced sequencing platform and bioinformatics capabilities to accelerate discoveries and translate findings into clinical applications. Join our collaborative research network to access larger datasets and multidisciplinary expertise.
For Pharma Companies
Accelerate your drug development and clinical trials by leveraging our advanced genomic sequencing and analytics for biomarker discovery, patient stratification, and pharmacogenomics. Explore strategic research partnerships to advance your understanding of disease mechanisms and therapeutic targets.
1
Contact Us
Reach out today to discuss how DTS Genomics can support your precision medicine initiatives. Our team of genomic specialists is ready to provide personalized consultations and demonstrations of our platform capabilities.
Request Information
The genomic revolution is transforming healthcare, and DTS Genomics is at the forefront of this paradigm shift. By combining cutting-edge sequencing technology with advanced analytics and clinical expertise, we're making comprehensive genomic insights accessible and actionable for healthcare providers, researchers, and patients worldwide.
Join us in building a future where genomic information empowers more precise diagnosis, more effective treatments, and more personalized prevention strategies. Together, we can unlock the full potential of the human genome to improve health outcomes and transform lives across the globe.
DTS Genomics is part of DTS S.A.
DTS S.A. is a member of The ND Pharma & Biotech Co.
Copyright Notice
© 2024 DTS S.A. All rights reserved. The content, including but not limited to text, graphics, images, and other materials, contained within this document (the "Material") is the exclusive property of DTS S.A. and is protected by international copyright laws.
Confidentiality & Proprietary Information
This Material contains confidential and proprietary information of DTS S.A. It is provided for the exclusive use of the intended recipient and for the specific purpose for which it was shared. Any unauthorized use, disclosure, distribution, or reproduction of this Material, in whole or in part, without the prior written consent of DTS S.A. is strictly prohibited and may result in legal action.
Restrictions on Use, Reproduction, and Distribution
No part of this Material may be copied, reproduced, distributed, transmitted, broadcast, displayed, sold, licensed, or otherwise exploited for any purpose whatsoever without the prior written consent of DTS S.A. Any permitted copies of the Material, or any portion thereof, must include this copyright notice and all other proprietary notices contained therein.
Forward-Looking Statements Disclaimer
This Material may contain forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and projections about future events and financial trends that may affect DTS S.A.'s business as it happens with DTS Genomics (branch of DTS S.A.). While DTS S.A. believes these forward-looking statements are reasonable, actual results could differ materially from those projected due to various factors, including, but not limited to, changes in market conditions, regulatory changes, and technological advancements. DTS S.A. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Inquiries
For any inquiries (including legal), reproduction requests, or questions regarding the use of this Material, please contact the DTS S.A. at [email protected]
DTS Genomics
ND Pharma & Biotech Co. Publishing Services
3-7, Temple Road, London, England, UK
www.ndpharmabiotech.com